CL2022000551A1 - Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl - Google Patents
Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de maglInfo
- Publication number
- CL2022000551A1 CL2022000551A1 CL2022000551A CL2022000551A CL2022000551A1 CL 2022000551 A1 CL2022000551 A1 CL 2022000551A1 CL 2022000551 A CL2022000551 A CL 2022000551A CL 2022000551 A CL2022000551 A CL 2022000551A CL 2022000551 A1 CL2022000551 A1 CL 2022000551A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- hexapirido
- oxazin
- magl inhibitors
- magl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la Fórmula general (I); en donde A, B, L, X, R1, R2, R3 y R4 son como se describen en la presente, composiciones que incluyen los compuestos, procesos para fabricar los compuestos y métodos para usar los compuestos como inhibidores de monoacilglicerol lipasa (MAGL).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19196089 | 2019-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022000551A1 true CL2022000551A1 (es) | 2022-11-18 |
Family
ID=67902336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022000551A CL2022000551A1 (es) | 2019-09-09 | 2022-03-04 | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20210094971A1 (es) |
| EP (1) | EP4028401B1 (es) |
| JP (1) | JP2022546853A (es) |
| KR (1) | KR20220061119A (es) |
| CN (1) | CN114364682A (es) |
| AR (1) | AR119910A1 (es) |
| AU (1) | AU2020344921A1 (es) |
| BR (1) | BR112022003704A2 (es) |
| CA (1) | CA3151218A1 (es) |
| CL (1) | CL2022000551A1 (es) |
| CO (1) | CO2022002339A2 (es) |
| CR (1) | CR20220091A (es) |
| IL (1) | IL289233A (es) |
| MX (1) | MX2022002554A (es) |
| PE (1) | PE20220904A1 (es) |
| TW (1) | TW202124392A (es) |
| WO (1) | WO2021048036A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| CN111566105A (zh) | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| CA3104928A1 (en) | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| CR20220104A (es) | 2019-09-12 | 2022-04-20 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl |
| JP2023539690A (ja) | 2020-09-03 | 2023-09-15 | エフ． ホフマン－ラ ロシュ アーゲー | 複素環式化合物 |
| WO2024071398A1 (ja) * | 2022-09-30 | 2024-04-04 | 小野薬品工業株式会社 | Ａｂｈｄ６アンタゴニスト |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| WO2016185279A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| US10323038B2 (en) * | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10385057B2 (en) * | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| TW201930300A (zh) * | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| CN111566105A (zh) * | 2018-01-08 | 2020-08-21 | 豪夫迈·罗氏有限公司 | 作为MAGL抑制剂的八氢吡啶并[1,2-α]吡嗪类化合物 |
| DK3768684T3 (da) * | 2018-03-22 | 2023-04-24 | Hoffmann La Roche | Oxazin-monoacylglycerol-lipase (MAGL)-hæmmere |
| CA3104928A1 (en) * | 2018-08-13 | 2020-02-20 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| SG11202012222TA (en) * | 2018-08-13 | 2021-01-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| PL3883936T3 (pl) * | 2018-11-22 | 2023-11-20 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne |
-
2020
- 2020-09-04 US US17/012,589 patent/US20210094971A1/en not_active Abandoned
- 2020-09-07 CN CN202080062559.0A patent/CN114364682A/zh active Pending
- 2020-09-07 CR CR20220091A patent/CR20220091A/es unknown
- 2020-09-07 PE PE2022000300A patent/PE20220904A1/es unknown
- 2020-09-07 AU AU2020344921A patent/AU2020344921A1/en active Pending
- 2020-09-07 AR ARP200102489A patent/AR119910A1/es unknown
- 2020-09-07 EP EP20772007.9A patent/EP4028401B1/en active Active
- 2020-09-07 WO PCT/EP2020/074897 patent/WO2021048036A1/en active Application Filing
- 2020-09-07 MX MX2022002554A patent/MX2022002554A/es unknown
- 2020-09-07 JP JP2022515504A patent/JP2022546853A/ja active Pending
- 2020-09-07 KR KR1020227007722A patent/KR20220061119A/ko unknown
- 2020-09-07 CA CA3151218A patent/CA3151218A1/en active Pending
- 2020-09-07 BR BR112022003704A patent/BR112022003704A2/pt unknown
- 2020-09-08 TW TW109130703A patent/TW202124392A/zh unknown
-
2021
- 2021-12-21 IL IL289233A patent/IL289233A/en unknown
-
2022
- 2022-02-28 CO CONC2022/0002339A patent/CO2022002339A2/es unknown
- 2022-03-04 CL CL2022000551A patent/CL2022000551A1/es unknown
- 2022-05-05 US US17/737,656 patent/US20220275005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021048036A1 (en) | 2021-03-18 |
| PE20220904A1 (es) | 2022-05-30 |
| EP4028401C0 (en) | 2023-11-22 |
| MX2022002554A (es) | 2022-03-22 |
| CO2022002339A2 (es) | 2022-03-08 |
| AU2020344921A1 (en) | 2022-02-17 |
| KR20220061119A (ko) | 2022-05-12 |
| JP2022546853A (ja) | 2022-11-09 |
| TW202124392A (zh) | 2021-07-01 |
| EP4028401A1 (en) | 2022-07-20 |
| BR112022003704A2 (pt) | 2022-05-24 |
| AR119910A1 (es) | 2022-01-19 |
| CA3151218A1 (en) | 2021-03-18 |
| CR20220091A (es) | 2022-04-01 |
| US20220275005A1 (en) | 2022-09-01 |
| IL289233A (en) | 2022-02-01 |
| US20210094971A1 (en) | 2021-04-01 |
| EP4028401B1 (en) | 2023-11-22 |
| CN114364682A (zh) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000551A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2022000556A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
| CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
| CO2020009567A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) de oxazina | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| BR112015023397A2 (pt) | benzoxazois substituídos e métodos de uso dos mesmos | |
| CO2022002336A2 (es) | Compuestos heterocíclicos | |
| CR11370A (es) | Inhibidores de quinasas simil polo | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| CO2022003062A2 (es) | Compuestos heterocíclicos | |
| CL2023000594A1 (es) | Compuestos heterocíclicos | |
| CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
| BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
| CL2023003154A1 (es) | Compuestos heterocíclicos | |
| CO2023016204A2 (es) | Inhibidores de nlrp3 | |
| CL2022002661A1 (es) | Derivados de benzodiazepinas como pam de gaba a gamma1 | |
| NI202100004A (es) | Compuestos de isoxazolina para controlar pl | |
| CO2023010212A2 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
| UY38056A (es) | Cetoximas sustituidas con piridazinonas como herbicidas |